Biopharmaceutical company developing antiviral and antifungal therapies, including long-acting influenza prevention and treatments for invasive fungal infections
Biopharmaceutical company developing antiviral and antifungal therapies, including long-acting influenza prevention and treatments for invasive fungal infections. Its programs include CD388, a long-acting antiviral prophylactic for seasonal and pandemic influenza, and earlier Cloudbreak targeted immunotherapy and biafungin echinocandin programs.